Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.


Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

 

International journal of endocrinology Том 15, №3, 2019

Back to issue

Latent autoimmune diabetes in adults: a modern look at the problem

Authors: Пашковська Н.В.
ВДНЗ України «Буковинський державний медичний університет», м. Чернівці, Україна

Categories: Endocrinology

Sections: Specialist manual

print version


Summary

У лекції подані сучасні відомості щодо латентного автоімунного діабету у дорослих (LADA). Наведені дані літератури щодо епідеміології, чинників і механізмів розвитку, клінічних особливостей цього захворювання. Виділені та охарактеризовані можливі варіанти перебігу LADA. Розкриті питання діагностичних особливостей, диференційної діагностики та зазначені перспективи лікування.

В лекции представлены современные сведения о латентном аутоиммунном диабете у взрослых (LADA). Приведены данные литературы относительно эпидемиологии, факторов и механизмов развития, клинических особенностей этого заболевания. Выделены и охарактеризованы возможные варианты течения LADA. Раскрыты вопросы диагностических особенностей, дифференциальной диагностики и обозначены перспективы лечения.

The lecture provides modern information on latent autoimmune diabetes in adults. Data of literature on the epidemiology, factors and mechanisms of development, clinical features of this disease are presented. The possible variants of latent autoimmune diabetes in adults course are identified and characterized. The questions of diagnostic features, differential diagnosis and the prospects of treatment are outlined.


Keywords

латентний автоімунний діабет у дорослих; LADA; цукровий діабет

латентный аутоиммунный диабет у взрослых; LADA; сахарный диабет

latent autoimmune diabetes in adults; diabetes mellitus


For the full article you need to subscribe to the magazine.


Bibliography

1. Ahlqvist E., Storm P., Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables // Lancet Diabetes Endocrinol. — 2018. — Vol. 6(5). — P. 361-369. DOI: 10.1016/S2213-8587(18)30051-2.
2. Groop L.C., Bottazzo G.F., Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis // Diabe-tes. — 1986. — Vol. 35(2). — P. 237-41. 
3. Irvine W.J., McCallum C.J., Gray R.S., Duncan L.J. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents // Lancet. — 1977. — Vol. 8020. — P. 1025-7. 
4. Juneja R., Palmer J.P. Type 1 1/2 diabetes: myth or rea–lity? // Autoimmunity. — 1999. — Vol. 29(1). — P. 65-83. 
5. Tuomi T., Groop L.C., Zimmet P.Z. et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease // Diabetes. — 1993. — Vol. 42(2). — P. 359-62. 
6. Zimmet P.Z., Tuomi T., Mackay I.R. et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decar-boxylase in diagnosis and prediction of insulin dependency // Diabet Med. — 1994. — Vol. 11(3). — P. 299-303. 
7. Turner R., Stratton I., Horton V. et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group // Lancet. — 1997. — Vol. 350(9087). — P. 1288-93. 
8. Groop L., Lundgren V., Lyssenko V. et al. and the Botnia Study Group: GADA positivity in relatives of type 2 diabetes or LADA // Diabetes. — 2005. — Vol. 54(2). — P. 160.
9. Punthakee Z., Goldenberg R., Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome // Can. J. Dia-betes. — 2018. — Vol. 42(Suppl. 1). — S. 10-S.15. DOI: 10.1016/j.jcjd.2017.10.003.
10. Koufakis T., Karras S.N., Zebekakis P., Kotsa K. Results of the First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults further highlight the need for a novel diabetes classification system // Ann. Transl. Med. — 2018. — Vol. 6(Suppl. 2). — S. 102. DOI: 10.21037/atm.2018.11.40.
11. Appel S.J., Wadas T.M., Rosenthal R.S., Ovalle F. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus // J. Am. Acad. Nurse Pract. — 2009. — Vol. 21(3). — P. 156-9. DOI: 10.1111/j.1745-7599.2009.00399.x.
12. Yasui J., Kawasaki E., Tanaka S. et al. Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan // PLoS One. — 2016. — Vol. 11(5). — e0155643. DOI: 10.1371/journal.pone.0155643. 
13. Pozzilli P., Pieralice S. Latent Autoimmune Diabetes in Adults: Current Status and New Horizons // Endocrinol. Metab. (Seoul). — 2018. — Vol. 33(2). — P. 147-159. DOI: 10.3803/EnM.2018.33.2.147.
14. Stenström G., Gottsäter A., Bakhtadze E., Berger B., Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell func-tion, and treatment // Diabetes. — 2005. — Vol. 54(Suppl. 2). — S. 68-72. 
15. Bruno G., Runzo C., Cavallo-Perin P. et al. Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin, Italy // Diabetes Care. — 2005. — Vol. 28(11). — P. 2613-9. 
16. Radtke M.A., Midthjell K., Nilsen T.I., Grill V. Hete–rogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trшndelag Health (HUNT) study // Diabetes Care. — 2009. — Vol. 32(2). — P. 245-50. DOI: 10.2337/dc08-1468. 
17. Buzzetti R., Di Pietro S., Giaccari A. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabe-tes // Diabetes Care. — 2007. — Vol. 30(4). — P. 932-8. 
18. Roh M.O., Jung C.H., Kim B.Y., Mok J.O., Kim C.H. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea // Acta Diabetol. — 2013. — Vol. 50(2). — P. 129-34. DOI: 10.1007/s00592-010-0228-y.
19. Yang Z., Wang K., Li T. et al. Childhood diabetes in China. Enormous variation by place and ethnic group // Diabetes Care. — 1998. — Vol. 21(4). — P. 525-9. 
20. Barinas-Mitchell E., Pietropaolo S., Zhang Y.J. et al. Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey // Diabetes. — 2004. — Vol. 53(5). — P. 1293-302. 
21. Maddaloni E., Lessan N., Al Tikriti A., Buzzetti R., Pozzilli P., Barakat M.T. Latent Autoimmune Diabetes in Adults in the United Arab Emir-ates: Clinical Features and Factors Related to Insulin-Requirement // PLoS One. — 2015. — Vol. 10(8). — e0131837. DOI: 10.1371/journal.pone.0131837.
22. Cervin C., Lyssenko V., Bakhtadze E. et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 dia-betes // Diabetes. — 2008. — Vol. 57(5). — P. 1433-7. DOI: 10.2337/db07-0299.
23. Тихонова Т.М. Обґрунтування підходів до терапії хворих на повільно прогресуючий автоімунний діабет дорослих // Міжнародний ендок-ринологічний журнал. — 2014. — № 7(63). — С. 28-32.
24. Andersen M.K., Lundgren V., Turunen J.A. et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diag-nosed after the age of 35 years // Diabetes Care. — 2010. — Vol. 33(9). — P. 2062-4. DOI: 10.2337/dc09-2188.
25. Haller K., Kisand K., Pisarev H. et al. Insulin gene VNTR, CTLA-4 +49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group // Tissue Antigens. — 2007. — Vol. 69. — P. 121-127. DOI: 10.1111/j.1399-0039.2006.00745.x.
26. Cosentino A., Gambelunghe G., Tortoioli C., Falorni A. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults // Ann. N. Y. Acad. Sci. — 2002. — Vol. 958. — P. 337-40. 
27. Vatay A., Rajczy K., Pozsonyi E. et al. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabe-tes mellitus // Immunol. Lett. — 2002. — Vol. 84(2). — P. 109-115. 
28. Земщиков В.С., Хамнуева Л.Ю., Быкова Н.М. Латентный аутоиммунный диабет взрослых // Сибирский медицинский журнал. — 2014. — № 2. — С. 16-20.
29. Hjort R., Ahlqvist E., Carlsson P.O. et al. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwe-gian HUNT Study // Diabetologia. — 2018. — Vol. 61(6). — P. 1333-1343. DOI: 10.1007/s00125-018-4596-0. 
30. Buzzetti R., Zampetti S., Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management // Nat. Rev. En-docrinol. — 2017. — Vol. 13(11). — P. 674-686. DOI: 10.1038/nrendo.2017.99.
31. Hernandez M., Mollo A., Marsal J.R. et al. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9 // BMC Endocr. Disord. — 2015. — Vol. 15. — P. 1. DOI: 10.1186/1472-6823-15-1.
32. Hawa M.I., Kolb H., Schloot N. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7 // Diabetes Care. — 2013. — Vol. 36(4). — P. 908-13. DOI: 10.2337/dc12-0931.
33. Maddaloni E., Pozzilli P. Getting it right for people with LADA // Diabetes Voice. — 2014. — Vol. 59. — P. 31-32.
34. Fourlanos S., Dotta F., Greenbaum C.J. et al. Latent autoimmune diabetes in adults (LADA) should be less latent // Diabetologia. — 2005. — Vol. 48(11). — P. 2206-12.
35. Leslie R.D., Palmer J., Schloot N.C., Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treat-ment // Diabetologia. — 2016. — Vol. 59(1). — P. 13-20. DOI: 10.1007/s00125-015-3789-z.
36. Fourlanos S., Perry C., Stein M.S. et al. A clinical screening tool identifies autoimmune diabetes in adults // Diabetes Care. — 2006. — Vol. 29(5). — P. 970-5. 
37. Pilla S.J., Balasubramanyam A., Knowler W.C. et al. Islet autoantibody positivity in overweight and obese adults with type 2 diabetes // Auto-immunity. — 2018. — Vol. 51(8). — P. 408-416. DOI: 10.1080/08916934.2018.1547711.
38. Tuomi T., Carlsson A., Li H. et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibo–dies // Diabetes. — 1999. — Vol. 48(1). — P. 150-7. 
39. Mollo A., Hernandez M., Marsal J.R. et al. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain // Diabetes Metab. Res. Rev. — 2013. — Vol. 29. — P. 446-451. DOI: 10.1002/dmrr.2411.
40. Genovese S., Bazzigaluppi E., Goncalves D. et al. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes // Eur. J. Endocrinol. — 2006. — Vol. 154. — P. 441-447.
41. Petrone A., Suraci C., Capizzi M. et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in Latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3 // Diabetes Care. — 2008. — Vol. 31. — P. 534-538. 
42. Zampetti S., Spoletini M., Petrone A. et al. Association of TCF7L2 gene variants with low GAD autoant ibody titre in LADA subjects (NIRAD Study 5) // Diabet Med. — 2010. — Vol. 27. — P. 701-704. DOI: 10.1111/j.1464-5491.2010.02997.x.
43. Zampetti S., Capizzi M., Spoletini M. et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6) // J. Clin. Endocrinol. Metab. — 2012. — Vol. 97. — P. 3759-3765. DOI: 10.1210/jc.2012-2037.
44. Myhill P., Davis W.A., Bruce D.G. et al. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study // Diabet Med. — 2008. — Vol. 25. — P. 1245-1250. DOI: 10.1111/j.1464-5491.2008.02562.x.
45. Lu J., Hou X., Zhang L. et al. Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes // Diabetes Metab. Res. Rev. — 2015. — Vol. 31. — P. 411-420. DOI: 10.1002/dmrr.2626.
46. Alam U., Jeziorska M., Petropoulos I.N. et al. Latent autoimmune diabetes of adulthood (LADA) is associated with small fibre neuropathy // Diabet Med. — 2018. doi: 10.1111/dme.13888. 
47. Arikan E., Sabuncu T., Ozer E.M., Hatemi H. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with type 2 diabetes mellitus // J. Diabetes Complications. — 2005. — Vol. 19. — P. 254-258.
48. Myhill P., Davis W.A., Bruce D.G. et al. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study // Diabet Med. — 2008. — Vol. 25. — P. 1245-1250. DOI: 10.1111/j.1464-5491.2008.02562.x.
49. Olsson L., Grill V., Midthjell K. et al. Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT Study // Diabetes Care. — 2013. — Vol. 36. — P. 3971-3978. DOI: 10.2337/dc13-0564.
50. Napoli N., Chandran M., Pierroz D.D. et al. Mechanisms of diabetes mellitus-induced bone fragility // Nat. Rev. Endocrinol. — 2017. — Vol. 13. — P. 208-219. DOI: 10.1038/nrendo.2016.153. 
51. Pieralice S., Pozzilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management // Diabetes Metab. J. — 2018. — Vol. 42(6). — P. 451-464. DOI: 10.3803/EnM.2018.33.2.147.
52. Kobayashi T., Nakanishi K., Murase T., Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM // Diabetes. — 1996. — Vol. 45. — P. 622-626.
53. Maruyama T., Tanaka S., Shimada A. et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93. — P. 2115-2121.
54. Davis T.M., Wright A.D., Mehta Z.M. et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with meta-bolic control (UKPDS 70) // Diabetologia. — 2005. — Vol. 48. — P. 695-702.
55. Cernea S., Buzzetti R., Pozzilli P. B-Cell protection and therapy for latent autoimmune diabetes in adults // Diabetes Care. — 2009. — Vol. 32. — P. 246-52. DOI: 10.2337/dc09-S317.
56. Jansen A., Rosmalen J.G., Homo-Delarche F. et al. Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest? // J. Autoimmun. — 1996. — Vol. 9. — P. 341-348.
57. Ellis S.L., Moser E.G., Snell-Bergeon J.K. et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial // Diabet Med. — 2011. — Vol. 28. — P. 1176-1181. DOI: 10.1111/j.1464-5491.2011.03331.x.
58. Johansen O.E., Boehm B., Grill V. et al. Beta-cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: ex-ploratory results from a 2-year double-blind randomized controlled study // Endocr. Rev. — 2012. — Vol. 33 (4 Suppl.). — SUN–LB1. DOI: 10.2337/dc13-1523.
59. Buzzetti R., Pozzilli P., Frederich R. et al. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA) // Diabetes Metab. Res. Rev. — 2016. — Vol. 32. — P. 289-296. DOI: 10.1002/dmrr.2717.
60. Pozzilli P., Leslie R.D., Peters A.L. et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials // Diabetes Obes Metab. — 2018. — Vol. 20. — P. 1490-1498. DOI: 10.1111/dom.13237.
61. Silko Y.V., Nikonova T.V., Shestakova M.V. Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin // Obesity and Metabolism. — 2016. — Vol. 13(2). — P. 3-6. DOI: 10.14341/OMET201623-6.
62. Pozzilli P., Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA // Ann. N. Y. Acad. Sci. — 2006. — Vol. 1079. — P. 90-98.
63. Chatenoud L., Bluestone J. CD3-specific antibodies: a portal to the treatment of autoimmunity // Nat. Rev. Immunol. — 2007. — Vol. 7. — P. 622-632.
64. Redondo M.J. LADA: time for a new definition // Diabetes. — 2013. — DOI: 62:339-40.10.2337/db12.

Similar articles

Обґрунтування підходів до терапії хворих на повільно прогресуючий автоімунний діабет дорослих
Authors: Тихонова Т.М. — ДУ «Інститут проблем ендокринної патології ім. В.Я. Данилевського НАМН України», м. Харків
International journal of endocrinology 7 (63) 2014
Date: 2015.02.11
Categories: Endocrinology
Sections: Clinical researches
The Prediction of Type 1 Diabetes Development and Diagnosis of Its Asymptomatic Phase Using Autoantibodies to Human Islets of Langerhans Long Before the Onset of the Disease
Authors: Зак К.П., Попова В.В.
ГУ «Институт эндокринологии и обмена веществ имени В.П. Комиссаренко НАМН Украины», г. Киев, Украина

International journal of endocrinology 7 (79) 2016
Date: 2016.12.20
Categories: Endocrinology
Sections: Specialist manual
Diabetes mellitus and Alzheimer’s disease
Authors: Pashkovska N.V. (1), Pankiv V.I. (2), Grinko N.V. (1), Pashkovska O.V. (3)
1 - Bukovinian State Medical University, Chernivtsi, Ukraine
2 - Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
3 - Charles University in Prague, Prague, the Czech Republic

International journal of endocrinology Том 15, №3, 2019
Date: 2019.07.09
Categories: Endocrinology
Sections: Specialist manual

Back to issue